Advertising
Showing 1 to 15 of 35 entries
WATCH
Trades around 15x PE and pays around a 4% dividend. Their future is in the vaccine side, but flu rather than Covid. Interesting company and worth studying further.
Pharma & Healthcare
PAST TOP PICK
(A Top Pick Mar 12/20, Up 36%) A world-class vaccine-maker. He likes pharmas going forward. SNY is facing a patent cliff, but have bought and are developing new drugs to solve this. He's happy to own and buy this.
Pharma & Healthcare
DON'T BUY
Done well recently as part of the vaccine trade. No real revenue growth over the last 5 years. Stagnant profits. Decent dividend. See his Top Picks today for exposure to healthcare.
Pharma & Healthcare
DON'T BUY
They are waiting for approval for their vaccine against COVID in Japan. They are pretty much an oncology firm. You have to compare against other companies in the sector. This one does fine with a PE of 8.8 times and the payout ratio is quite low. The dividends and cash flow are not growing, however. They have to come out with a blockbuster product. See his top picks today for a preferable.
Pharma & Healthcare
BUY
A very good company. Pays a 3.5% dividend yield. Historically, he expected more from their Covid vaccine, though.
Pharma & Healthcare
PAST TOP PICK

(A Top Pick Mar 12/20, Up 36%) The same idea as GSK. Hasn't done a whole lot. They are actually working on a Covid vaccine. In the meantime, non-covid visits have been decreased so there has been a hit on prescriptions. Once it comes back, they should do fine.

Pharma & Healthcare
COMMENT
In late-2019, a new CEO arrive to turn things around by spinning off the so-so consumer business and making small acquisitions. However, Covid hit them hard, and their vaccine development has disappointed. Reported a solid quarter this morning with a slight revenue miss, but strong earnings beat and bullish guidance for 2021. The stock rose 2%. Will it get its groove back?
Pharma & Healthcare
BUY
A French pharma. He bought this not for its vaccine, but because it's a well-run pharma, not facing patent expirations, and has good growth and returns in the future. He doesn't know where their vaccine stands now, but if it works, it will certainly boost the stock. Has strong dividend and earnings growth.
Pharma & Healthcare

Unlock Panic-Proof Portfolio and Top Stock Picks

Become a member Or, Sign In
TOP PICK
Stockchase Research Editor: Michael O'Reilly SNY is a French biotech that produces a wide range of vaccines and pharmaceuticals by prescription. It produces a drug for children aged 6-11 years with atopic dermatitis. Sales of the drug jumped almost 70% last year and it is on pace to earn the company $12 billion in revenues in the near future. The company is also vying to be another COVID-19 vaccine producer as it plans to introduce Phase 3 trials on a prospective candidate this month. It pays an excellent dividend, backed by a 38% payout ratio. We would buy SNY with a stop-loss at $45, looking towards an initial target of $61 -- 20% upside. Yield 3.36% (Analysts’ price target is $61.38)
Pharma & Healthcare
TOP PICK
It is not economically sensitive even though the stock is getting hit. It is one of the biggest vaccine manufacturers in the world. They are working on a CoVid19 vaccine and they own an arthritis drug that could be a possible drug for treatment of CoVid19. (Analysts’ price target is $56.93)
Pharma & Healthcare
TOP PICK
A French drug company that is starting to run. Th patent cliff has occurred and they have been busy bringing in new products. They also have a very profitable consumer health business. Yield 3.44% (Analysts’ price target is $54.17)
Pharma & Healthcare
TOP PICK
A great global business. A bit boring, but not worries about a big drug coming off patent. He expects healthy dividend growth over time. (Analysts’ price target is $52.00)
Pharma & Healthcare
PAST TOP PICK
(A Top Pick Aug 14/18, Up 7%) One of the largest pharma companies in the world. Their major products are looking good and their product pipeline has lots of opportunities.
Pharma & Healthcare
WEAK BUY
It hasn't done much lately. Boring. Little volatility. They have a great vaccine business and some exposure to Africa. Slow growth, but you get a great dividend. A conservative play.
Pharma & Healthcare
PAST TOP PICK
(A Top Pick Jul 04/18, Up 13%) One of three drug stocks he still owns. He likes the product selection and bought into it when they had a few key drugs that were coming off patent and the stock price had dropped. He has confidence they will continue to add new profitable drugs.
Pharma & Healthcare
Showing 1 to 15 of 35 entries

Sanofi-Aventis(SNY-N) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 4

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 2

Total Signals / Votes : 6

Stockchase rating for Sanofi-Aventis is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Sanofi-Aventis(SNY-N) Frequently Asked Questions

What is Sanofi-Aventis stock symbol?

Sanofi-Aventis is a American stock, trading under the symbol SNY-N on the New York Stock Exchange (SNY). It is usually referred to as NYSE:SNY or SNY-N

Is Sanofi-Aventis a buy or a sell?

In the last year, 6 stock analysts published opinions about SNY-N. 4 analysts recommended to BUY the stock. 2 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Sanofi-Aventis.

Is Sanofi-Aventis a good investment or a top pick?

Sanofi-Aventis was recommended as a Top Pick by on . Read the latest stock experts ratings for Sanofi-Aventis.

Why is Sanofi-Aventis stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Sanofi-Aventis worth watching?

6 stock analysts on Stockchase covered Sanofi-Aventis In the last year. It is a trending stock that is worth watching.

What is Sanofi-Aventis stock price?

On 2021-10-20, Sanofi-Aventis (SNY-N) stock closed at a price of $49.05.